High CR/CRi rates were shown for olverembatinib plus blinatumomab in relapsed/refractory Ph-positive chronic myeloid leukemia and B-ALL.
Opinion|Videos|January 9, 2026
Early Real-World Experience with Revumenib Outside of a Clinical Trial Setting: A Single Center Retrospective Review of Efficacy and Tolerability
Author(s)David Sallman, MD
Discover the latest insights on Revumenib's real-world effectiveness in treating acute myeloid leukemia, presented at ASH 2025.
Advertisement
David Sallman, MD discusses early real-world experience with Revumenib outside of a clinical trial setting: A single center retrospective review of efficacy and tolerability.
Advertisement
Related to this article
PRAME-directed therapies represent a novel approach in the treatment of advanced melanoma.
Roswell Park Comprehensive Cancer Center investigators will deliver 21 presentations at the AHNS 12th International Conference on Head and Neck Cancer.
Pelareorep plus a checkpoint inhibitor earned FDA fast track designation for pretreated, inoperable, recurrent, or metastatic squamous cell anal carcinoma.
Older age independently predicted higher non-relapse mortality and inferior overall survival outcomes after PTCy-based unrelated donor transplant.
The IL-10–expressing anti-CD19 CAR T-cell therapy produced a 92.9% complete response rate and a 92.9% 1-year overall survival rate in high-risk relapsed/refractory DLBCL.
The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
4
Dr Falchi on Critical Unmet Needs and Important Next Steps in DLBCL
5